Compare USEG & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USEG | ATNM |
|---|---|---|
| Founded | 1966 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.5M | 42.0M |
| IPO Year | 1995 | 2013 |
| Metric | USEG | ATNM |
|---|---|---|
| Price | $0.89 | $1.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.50 | ★ $4.50 |
| AVG Volume (30 Days) | ★ 7.2M | 242.1K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.21 | 14.17 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,379,000.00 | $90,000.00 |
| Revenue This Year | $114,854.51 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $0.66 | $0.95 |
| 52 Week High | $2.75 | $1.95 |
| Indicator | USEG | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 43.30 | 55.86 |
| Support Level | $0.66 | $1.25 |
| Resistance Level | $1.08 | $1.56 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 4.89 | 70.33 |
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business properties and operations in the Rockies region (Montana, Wyoming, and North Dakota), the Mid-Continent (Oklahoma, Kansas, and North and East Texas), and the West Texas, South Texas, and Gulf Coast regions. The company generates revenue from its interest in the sales of oil and natural gas production. The group operates in the exploration and production segment of the oil and gas industry, onshore in the United States.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.